Ann Kristin Led is stepping down as CEO of MedTrace as the company sharpens its focus on expanding its presence in the United States. Nicholas Borys M.D., Chief Medical Officer, will assume the role of Interim CEO effective as of today.
MedTrace, an innovator in PET diagnostic imaging, today announced that Ann Kristin Led is departing from her role as CEO, following a mutual agreement with the Board of Directors. The company expresses its sincere gratitude for her significant contributions over the years, both as CFO and subsequently as CEO, and wishes her success in her future endeavors.
This leadership transition aligns with the Board and Executive Management Team’s strategic decision to prioritize and strengthen MedTrace’s presence in the United States. Consequently, the CEO role has evolved to require an increased physical presence in the US market.
Nicholas Borys M.D. will continue his role as CMO and take over as interim CEO for MedTrace until a new CEO is in place. He says:
“I am honored to take on the role of interim CEO during this important transition for MedTrace. As we deepen our focus on the US market, I remain committed to advancing our strategic priorities and ensuring continuity across our trials. I would like to thank Ann Kristin for her leadership and dedication to MedTrace, and I look forward to working closely with the team as we continue to deliver on our mission.”
Nicholas Borys, M.D. is a skilled and experienced healthcare executive with over 25 years’ experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.
Among his accomplishments, he led drug development at IMUNON, Amersham, and Hoffmann-La Roche, and successfully led and completed four new drug applications.
Erik Strömqvist, Chairman of the Board, says:
“The Board is highly appreciative of the strong and promising pipeline MedTrace has built for the future. However, it has become essential to sharpen our strategic focus on the United States and prepare the company for the next financing round. With Dr. Nicholas Borys serving as interim CEO—based in the US and bringing extensive global experience in clinical research and drug development across cardiology, oncology, neurology, and nuclear medicine—we are confident that MedTrace is well-positioned to advance this next phase.”
As part of the organizational changes, Lykke Rømer, currently Head of Finance, will assume the role as CFO. Pia Skanvig Maretti, Director of People and Communication, will assume the role as Vice President of Business Development and People.
About MedTrace
MedTrace focus on radiopharmaceuticals with an ultra-short half-life and is currently working to make 15O-water available in clinical practice. The company’s ongoing Phase III clinical trial in the USA is evaluating the diagnostic accuracy and safety of 15O-water as a tracer for PET scans of patients with suspected coronary artery disease.
MedTrace’s technology is already in use in clinical practice in Denmark at Rigshospitalet, Copenhagen, and Aarhus University Hospital, Aarhus, under magistral exemption and exemption from CE marking issued by the Danish Medicines Agency. To this day, Aarhus University Hospital has scanned more than 3,000 patients with 15O-water produced by MedTrace’s technology and medical devices.
For more information, please contact:
Sandra Meersohn Meinecke
sandra@thecentral.dk
+45 53 56 51 61
